Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC.

ABSTRACT:

Introduction

SCLC accounts for approximately 250,000 deaths worldwide each year. Acquisition of adequate tumor biopsy samples is challenging, and liquid biopsies present an alternative option for patient stratification and response monitoring.

Methods

We applied whole genome next-generation sequencing to circulating free DNA (cfDNA) from 39 patients with limited-stage (LS) SCLC and 30 patients with extensive-stage SCLC to establish genome-wide copy number aberrations and also performed targeted mutation analysis of 110 SCLC associated genes. Quantitative metrics were calculated for copy number aberrations, including percent genome amplified (PGA [the percentage of genomic regions amplified]), Z-score (a measure of standard deviation), and Moran's I (a measure of spatial auto

SUBMITTER: Mohan S 

PROVIDER: S-EPMC7001105 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature